from Genetic Engineering News by Richard A. Stein –
In recent years, scientists have adopted a gene-centric view of cancer, a tendency to see each malignant transformation as the consequence of alterations in a discrete number of genes or pathways. These alterations are, fortunately, absent from healthy cells, but they pervert malignant cells.
An increasing number of clinicians are adding the cancer transcriptome to their precision medicine program. They have found that the transcriptome is important in identifying clinically impactful results.
The gene-centric view takes in molecular landscapes illuminated by genomic and transcriptomic technologies. For example, genomes can be cost-effectively sequenced within hours. Such capabilities have made it possible to interrogate associations between genotypes and phenotypes for increasing numbers of conditions, and to collect data from progressively larger patient groups.
As genomic and transcriptomic technologies rise, they reveal much—but much remains hidden, too. Perhaps these technologies are less like the sun and more like the proverbial streetlight, the one that narrows our searches because we’re inclined to stay in the light, even though what we hope to find may lie in the shadows.
“Each individual study that looks at the cancer transcriptome is impressive and tells a convincing story, but if we put several high-quality papers together, there are very few genes that overlap,” says Henry H. Heng, Ph.D., professor of molecular medicine, genetics, and pathology at Wayne State University. “This shows that something is wrong.” (read more…)
Source – Genetic Engineering News
from Genetic Engineering News by Richard A. Stein –
In recent years, scientists have adopted a gene-centric view of cancer, a tendency to see each malignant transformation as the consequence of alterations in a discrete number of genes or pathways. These alterations are, fortunately, absent from healthy cells, but they pervert malignant cells.
An increasing number of clinicians are adding the cancer transcriptome to their precision medicine program. They have found that the transcriptome is important in identifying clinically impactful results.
The gene-centric view takes in molecular landscapes illuminated by genomic and transcriptomic technologies. For example, genomes can be cost-effectively sequenced within hours. Such capabilities have made it possible to interrogate associations between genotypes and phenotypes for increasing numbers of conditions, and to collect data from progressively larger patient groups.
As genomic and transcriptomic technologies rise, they reveal much—but much remains hidden, too. Perhaps these technologies are less like the sun and more like the proverbial streetlight, the one that narrows our searches because we’re inclined to stay in the light, even though what we hope to find may lie in the shadows.
“Each individual study that looks at the cancer transcriptome is impressive and tells a convincing story, but if we put several high-quality papers together, there are very few genes that overlap,” says Henry H. Heng, Ph.D., professor of molecular medicine, genetics, and pathology at Wayne State University. “This shows that something is wrong.” (read more…)
Source – Genetic Engineering News
Related Posts
RNA sequencing reveals functional chimeric mRNAs in mammalian immunity
Atlas of the brain’s striatum could guide researchers to new drug treatments
Immune cells offer insights on billion-dollar virus
A functionally integrated cross-tissue alternative splicing program during short-term calorie restriction
Dietary oxidized plant sterol shifts macrophage state to fuel aortic inflammation
Unlocking the past – new method helps gain insights into old tissue
Novel AI model trained on RNA-Seq data accurately detects key gene mutations and predicts biomarkers across 32 cancer types
Transcriptomic aging clock reveals age-related molecular patterns in opioid dependence
RNA sequencing helps predict stem cell transplant benefit in pediatric AML
Protein ‘switch’ determines whether liposarcoma cells will become aggressive
Precursor tRNAs sense temperature changes: heat stress-induced capped pre-tRNAs suppress protein synthesis
Ketamine increases neuroplasticity in female mice but not in males
Somatic mutations linked to vascular damage in progeria
Scientists map dormant cancer cells’ hideouts, opening new targets for treatment
Soluble signals released by neighboring cells direct how the human kidney is built
Genetics influence how cancer arises – and how it evolves
RNA-based testing uncovers extraordinary diversity in mutations driving lung cancer
Study offers new insights into why ex-smokers remain at elevated risk of lung disease
Learning the grammar of gene regulation
New findings could transform new treatment for rare brain tumor astroblastoma
from Genetic Engineering News by Richard A. Stein –
In recent years, scientists have adopted a gene-centric view of cancer, a tendency to see each malignant transformation as the consequence of alterations in a discrete number of genes or pathways. These alterations are, fortunately, absent from healthy cells, but they pervert malignant cells.
An increasing number of clinicians are adding the cancer transcriptome to their precision medicine program. They have found that the transcriptome is important in identifying clinically impactful results.
The gene-centric view takes in molecular landscapes illuminated by genomic and transcriptomic technologies. For example, genomes can be cost-effectively sequenced within hours. Such capabilities have made it possible to interrogate associations between genotypes and phenotypes for increasing numbers of conditions, and to collect data from progressively larger patient groups.
As genomic and transcriptomic technologies rise, they reveal much—but much remains hidden, too. Perhaps these technologies are less like the sun and more like the proverbial streetlight, the one that narrows our searches because we’re inclined to stay in the light, even though what we hope to find may lie in the shadows.
“Each individual study that looks at the cancer transcriptome is impressive and tells a convincing story, but if we put several high-quality papers together, there are very few genes that overlap,” says Henry H. Heng, Ph.D., professor of molecular medicine, genetics, and pathology at Wayne State University. “This shows that something is wrong.” (read more…)
Source – Genetic Engineering News
Related Posts
RNA sequencing reveals functional chimeric mRNAs in mammalian immunity
Atlas of the brain’s striatum could guide researchers to new drug treatments
Immune cells offer insights on billion-dollar virus
A functionally integrated cross-tissue alternative splicing program during short-term calorie restriction
Dietary oxidized plant sterol shifts macrophage state to fuel aortic inflammation
Unlocking the past – new method helps gain insights into old tissue
Novel AI model trained on RNA-Seq data accurately detects key gene mutations and predicts biomarkers across 32 cancer types
Transcriptomic aging clock reveals age-related molecular patterns in opioid dependence
RNA sequencing helps predict stem cell transplant benefit in pediatric AML
Protein ‘switch’ determines whether liposarcoma cells will become aggressive
Precursor tRNAs sense temperature changes: heat stress-induced capped pre-tRNAs suppress protein synthesis
Ketamine increases neuroplasticity in female mice but not in males
Somatic mutations linked to vascular damage in progeria
Scientists map dormant cancer cells’ hideouts, opening new targets for treatment
Soluble signals released by neighboring cells direct how the human kidney is built
Genetics influence how cancer arises – and how it evolves
RNA-based testing uncovers extraordinary diversity in mutations driving lung cancer
Study offers new insights into why ex-smokers remain at elevated risk of lung disease
Learning the grammar of gene regulation
New findings could transform new treatment for rare brain tumor astroblastoma
Stay Connected
Submit a Post to the Blog
Recent Posts
Subscribe to the RNA-Seq Blog
RNA-Seq Products & Services